MicroRNA signatures of platinum-resistance in ovarian cancer

Eur J Gynaecol Oncol. 2015;36(1):16-20.

Abstract

Objectives: The authors utilized a microRNA (miRNA) array to compare the differentially expressed miRNAs in platinum-resistant associated ovarian cancer cells.

Materials and methods: The differential expression of microRNA between COC1 (DDP-sensitive) and platinum-resistant COC1/DDP (DDP-resistant) tumor cell lines was determined using microarray. Expression levels were further validated by real-time quantitive polymerase chain reaction (qRT-PCR).

Results: The authors identified that several miRNAs are altered in collected 86 samples of human ovarian cancer cell-lines, with four significantly deregulated miRNAs and 13 upregulated miRNAs. Of which, miR-141-3p was the most differentially expressed miRNA between COC1 group (1.7833 ± 0.7213) and COC1/DDP group (14.0433 ± 4.4895) (p < 0.05). Additionally, the product curve of PCR amplification indicated that miR-141-3p had a significant higher expression level in chemotherapy resistant group (n = 20) rather than in chemotherapy sensitive group (n = 20) (9.56 ± 1.04 vs. 1.59 ± 0.91, p < 0.05).

Conclusions: The present results suggest that miR-141-3p might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use
  • Carboplatin / therapeutic use
  • Carcinoma / drug therapy*
  • Carcinoma / genetics
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Gene Expression Profiling
  • Humans
  • MicroRNAs / analysis*
  • Middle Aged
  • Oligonucleotide Array Sequence Analysis
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / genetics
  • Up-Regulation

Substances

  • Antineoplastic Agents
  • MicroRNAs
  • Carboplatin